<DOC>
	<DOCNO>NCT00725296</DOCNO>
	<brief_summary>This prospective , open-label , 1-arm , multicenter observational study determine dose time interval Remicade ( Infliximab ) infusion psoriatic arthritis ( PsA ) .</brief_summary>
	<brief_title>Investigation 9 Consecutive Infusions Remicade Psoriatic Arthritis Austria ( Study P04264 )</brief_title>
	<detailed_description>This study population choose non-probability sample .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Participants active progressive psoriatic arthritis respond inadequately diseasemodifying antirheumatic drug . All accord contraindication label especially : Participants tuberculosis severe infection sepsis , abscess , opportunistic infection . Participants moderate severe heart failure ( NYHA class III/IV ) . Participants history hypersensitivity infliximab murine protein , excipients .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>